Dupixent sales skyrocket with 'expanded indications'

Generating KRW 14 trillion in nine months

Topped KRW 5 trillion in global sales in Q3 2024…up 18.1% YoY

Besides atopic dermatitis, its strength is securing added indications to treat asthma·esophagitis·COPD

Sales for 'Dupixent,' a biological agent developed by Sanofi, continue to skyrocket.

 

Net sales for Dupixent from Q1 to Q3 of 2024 reached 10 billion euros.

 

The analysis suggests that Dupixent's added indications to treat various immune diseases, including atopic dermatitis, asthma, esophagitis, and chronic obstructive pulmonary disease (COPD), have contributed to its continued sales increase.

 

According to Sanofi's performance report on October 29, Dupixent's Q3 global sales amounted to 3.476 billion euros (about KRW 5.2 trillion), up 18.1% year-over-year (YoY).

 

Dupixent's sales for 2024 were 9.614 billion euros (about KRW 14.4 trillion), up 24.5% compared to Q3 of last year.

 

Dupixent

After recording 2.835 billion euros in Q1 2024, it surpassed 3 billion euros in Q2.

 

Dupixent generated 3.476 billion euros in Q3, up 115.4% compared to 1.614 billion euros in Q1 2022.

 

Dupixent is the first biological agent to target the signaling transmission of interleukin (IL)-4 and IL-13, which are the main causes of type 2 inflammation.

 

Dupixent was developed from a global collaboration agreement between Sanofi and Regeneron Pharmaceuticals.

 

The drug received marketing authorization as a treatment for atopic dermatitis in various countries, including South Korea, the United States, Canada, Europe, Japan, and Australia.

 

Launched in the global market in 2018, Dupixent continues to generate sales growth.

 

After recording 107 million euros in Q1 2018, it generated more than 1 billion euros (about KRW 1.5 trillion) in Q1 2022.

 

Since then, Dupixent has grown into a blockbuster drug with annual sales of more than 10 billion euros (about KRW 15 trillion).

 

Sanofi expects Dupixent's yearly sales to reach around 13 billion euros this year.

 

Confirmed safety and efficacy…added indications contributing to sales hike

Dupixent, Sanofi

Dupixent is regarded as a biological agent that has proven extended efficacy and safety.

 

Unlike conventional immune inhibitors, this drug reduced the number of side effects in clinical and real-world data.

 

It has the efficacy in targeting only the inflammatory responses of Th2 cells.

 

Biologics are medicines that are manufactured based on pathogenic microorganisms such as proteins, antibodies, nucleotides, and cells.

 

This agent effectively targets proteins and cells to treat diseases, and it has the advantage of lowering side effects compared to chemical agents.

 

Dupixent's other advantage is its continued addition of indications.

 

In 2017, the U.S.

 

Food and Drug Administration (FDA) granted approval to Dupixent for its indication to treat atopic dermatitis.

 

The following year, it expanded prescription areas to treat patients with moderate or higher symptoms.

 

In the United States, Dupixent is the only asthma drug to target all ages.

 

Since then, Dupixent has expanded the scope of approval to various immune diseases, including chronic sinusitis with nasal polyps, nodular rashes, and eosinophilic esophagitis.

 

Dupixent has recently added an indication to treat COPT.

 

On October 27, the FDA approved Dupixent for the treatment of COPD.

 

Dupixent is the first biological agent to secure a COPD indication.

 

Dupixent has shown strength in diseases triggered by type 2 inflammation, from atopic dermatitis to asthma, chronic sinusitis with nasal polyps, and eosinophilic esophagitis.

 

It is expected to add additional indications for diseases caused by similar mechanisms.

 

Currently, Sanofi is conducting a Phase 3 clinical study of Dupixent, aiming to secure indications to treat chronic idiopathic urticaria (CSU), chronic pruritus (CPUO), and bullous pemphigus (BP).